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A Missense Mutation in PRPF6 Causes
Impairment of pre-mRNA Splicing
and Autosomal-Dominant Retinitis Pigmentosa
Goranka Tanackovic,1 Adriana Ransijn,1 Carmen Ayuso,3 Shyana Harper,2 Eliot L. Berson,2
and Carlo Rivolta1,*
Retinitis pigmentosa (RP) is an inherited form of retinal degeneration that leads to progressive visual-field constriction and blindness.
Although the disease manifests only in the retina, mutations in ubiquitously expressed genes associated with the tri-snRNP complex of
the spliceosome have been identified in patients with dominantly inherited RP. We screened for mutations in PRPF6 (NM_012469.3),
a gene on chromosome 20q13.33 encoding an essential protein for tri-snRNP assembly and stability, in 188 unrelated patients with auto-
somal-dominant RP and identified amissensemutation, c.2185C>T (p.Arg729Trp). This change affected a residue that is conserved from
humans to yeast and cosegregatedwith the disease in the family in which it was identified. Lymphoblasts derived from patients with this
mutation showed abnormal localization of endogenous PRPF6 within the nucleus. Specifically, this protein accumulated in the Cajal
bodies, indicating a possible impairment in the tri-snRNP assembly or recycling. Expression of GFP-tagged PRPF6 in HeLa cells showed
that this phenomenon depended exclusively on the mutated form of the protein. Furthermore, analysis of endogenous transcripts in
cells from patients revealed intron retention for pre-mRNA bearing specific splicing signals, according to the same pattern displayed
by lymphoblasts with mutations in other PRPF genes. Our results identify PRPF6 as the sixth gene involved in pre-mRNA splicing
and dominant RP, corroborating the hypothesis that deficiencies in the spliceosome play an important role in the molecular pathology
of this disease.Mutations inmore than50genes cause retinitis pigmentosa
(RP [MIM 268000]), a form of retinal degeneration with an
estimated prevalence of 1 in ~4,000 individuals.1,2 Patients
with this condition experience a progressive decline of
retinal function, usually starting with night blindness,
that often leads to the complete loss of vision at the end
stage.3 RP is inherited as a dominant, recessive, or X-linked
trait and very rarely as a non-Mendelian phenotype.4 The
course of the disease can be slowed with vitamin A supple-
mentation.5 Most genes associated with nonsyndromic RP
have a retina-prevalent expression and/or produce proteins
that have a clear biochemical or structural role within the
retinal or the retinal pigment epithelium cells. Other RP
genes, however, have amorewidespread expressionpattern
or are present in all human tissues and nonetheless cause
ocular-restricted symptoms.1
With respect to ubiquitously expressed genes, mutations
in a few cause autosomal-dominant RP (adRP) and encode
PRPF31 (MIM 606419), PRPF8 (MIM 607300), PRPF3
(MIM 607301), RP9 (MIM 607331), and hBRR2 (MIM
601664),6–12 i.e., five out of the several dozen proteins
composing the spliceosome, a machinery that is essential
for pre-mRNA processing in all eukaryotes. This macromo-
lecular structure is constituted by five small nuclear ribonu-
cleoproteins (snRNPs), U1, U2, U4, U5, and U6, as well as
more than a hundred other non-snRNP-specific proteins
(reviewed in Wahl et al.13). Intron removal by the spliceo-
some occurs through a series of sequential reactions that1Department of Medical Genetics, University of Lausanne, CH-1005 Lausan
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The Ameinvolve the dynamic assembly and disassembly of snRNP
subcomplexes. Within each round of splicing, the U4/
U6.U5 complex (the tri-snRNP) is assembled through the
interaction of the U4/U6 di-snRNPwith U5, which is medi-
ated by splicing factors PRPF31 and PRPF6.14,15 Interest-
ingly, all the pre-mRNA splicing factor genes associated
with adRP encode components of the tri-snRNP and, with
the exception of RP9, have been proven to affect the
assembly and/or disassembly of this particle.16–20 Within
the tri-snRNP, PRPF6 acts as a molecular bridge between
the U5 snRNP and the di-snRNP.15 Furthermore, data
from electron microscopy and protein-protein interaction
analyses21,22 indicate that PRPF6 binds to 4 out of 5 tri-
snRNP proteins involved in adRP, constituting the struc-
tural heart of the particle itself (Figure 1). On the basis of
previous biochemical knowledge on this protein and the
involvement of other tri-snRNP components in adRP, we
reasoned that PRPF6 could be a good candidate gene for
this condition.
We screened formutations in all 21 exons of this gene on
chromosome 20q13.33 in index patients from 188 families
with adRP. This study involved human subjects, was carried
out in accordance with the tenets of the declaration of
Helsinki, and was approved by the institutional review
boards of the University of Lausanne, Harvard Medical
School, and the Massachusetts Eye and Ear Infirmary. All
participants gave written, informed consent before they
donated 10–30 ml of blood for genomic DNA extraction orne, Switzerland; 2The Berman-Gund Laboratory for the Study of Retinal
, Boston, Massachusetts 02114, USA; 3Genetics Department, IIS-Fundacio´n
Genetics. All rights reserved.
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Figure 1. Schematic and Partial Representation of the Spliceo-
somal Tri-snRNP Particle and of Proteins Associated with adRP
This image graphically depicts current data on protein-protein
interactions and the electron-microscopy-based physical structure
of tri-snRNP components. Elements of the U5 snRNP are in
different shades of red, and those belonging to the U4/U6 snRNP
are in shades of blue. Names of proteins found to be associated
with adRP are in white ink. The dotted line indicates that RP9
interacts with PRPF3, although it is not a core component of the
tri-snRNP.
Figure 2. Relative Position, DNA Sequence, and Effects
of c.2185C>T in PRPF6
(A) PRPF6 (red box) is a 21 exon gene located at the end of the long
arm of chromosome 20. The c.2185C>T mutation (red vertical
line within the cDNA representation) lies in exon 16 and causes
the Arg>Trp substitution at codon 729. Arg729 (red pin) lies
within the eighth HAT (Half-a-TRP) domain of the encoded
protein, in the middle of the PRPF6 moiety (blue bar) responsible
for its interaction with the U4/U6 snRNP.
(B) Phylogenetic alignment of part of the HAT domain containing
Arg729, indicated by the arrowhead. Non-conserved residues are
shaded.lymphoblast immortalization. DNA regions to be analyzed
were amplified by PCR with the primers reported in Table
S1, purified, and subsequently sequenced by standard
Sanger sequencing with a 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA). Among the many DNA
changes detected (Table S2), one was a missense variation
causing an arginine-to-tryptophan (positively charged to
hydrophobic amino acid) substitution (p.Arg729Trp
[c.2185C>T]) at codon 729 in exon 16 (Figure 2A). This
variant, which was not reported in public sequence reposi-
tories (including the 1000 Genomes project database),
affected a PRPF6 residue that seems to be invariant in all
eukaryotic kingdoms, with the exception of the class of
insects (Figure 2B). Arginine 729 is part of one of the
HAT (half a TPR) repeats that are present in the C-terminal
part of PRPF6. Such domains are characterized by the
presence of three aromatic residues with conserved spacing
and are involved in protein-protein interactions.23 The
missense mutation was present in a male patient of
European descent (ID: 001-173, IV-1 in Figure 3A) who
reported a family history of RP but was absent in 1,078
chromosomes fromethnicallymatched control individuals.644 The American Journal of Human Genetics 88, 643–649, May 13,Additional genetic screening revealed the sameDNAchange
in the patient’s affected brother; no other members of this
family were available for further investigation (Figure 3A).2011
Figure 3. Pedigree, Fundus Photographs, and Electroretino-
grams of Patient 001-173
(A) The family tree of the index patient indicates dominant inher-
itance of RP over three, possibly four, generations.
(B) Fundus photographs of patient 001-173’s right eye at age 37
(top) and 55 (bottom). Photographs reveal progression of retinitis
pigmentosa over this period (see text).
(C) Full-field ERGs from a normal control and patient 001-173 at
age 37 and age 55; patient’s responses (right eye, illustrated) to
0.5 Hz white light flashes under dark-adapted conditions and
30 Hz white flicker at age 55 are substantially smaller than
responses at age 37 (see text). Vertical lines indicate time of stim-
ulus onset.At an age of 37 years, patient 001-173 was first examined
by one of us (E.L.B.) in 1988 for night deficiency and loss
of side vision. At this initial examination he had a best-
corrected visual acuity of 20/30 O.D. (right eye) and 20/40
O.S. (left eye). Slit-lamp examination showed central poste-
rior subcapsular cataractsO.U. (in both eyes). Fundus exam-
inationof eacheye showedanormaldisc, someatrophy just
temporal to the disc, clearmacula, attenuated retinal arteri-
oles, and bone spicule pigment 360 around the periphery
(Figure 3B, top). His final dark adaptation threshold was
elevated 3.0 log units. His Goldmann visual field in a V-4e
white test light was constricted to a 25 diameter with
aperipheral crescent in eacheye.His full-field electroretino-
grams (ERGs) were substantially reduced, and he had dark-
adapted mixed cone-rod responses to 0.5 Hz white light of
5.6 mV O.D. and 4.9 mV O.S. (lower norm ¼ 350 mV) and
cone responses to 30 Hz white flicker of 0.4 mV O.D. andThe Ame0.7 mV O.S. (lower norm ¼ 50 mV) (Figure 3C). He was last
examined in 2007 at age 55. At that time he reported that
he had cataract surgery O.S. in 1999 and O.D. in 2000 and
a reoperation O.D. in 2001. After the reoperation in 2001,
he had extensive inflammation and never recovered acuity
O.D.TheacuityO.S. graduallydecreased from1999 to2007.
He also noted further loss of peripheral vision O.U. during
this period. His best-corrected vision was hand motions
O.D. and 20/100 O.S. Slit-lamp examination showed pseu-
dophakia O.U. Fundus examination of each eye showed
waxy pallor of each disc, atrophy of the retinal pigment
epithelium and prominent choroidal vessels in each
macula, attenuated retinal vessels, and bone spicule
pigment visible in the midperiphery (Figure 3B, bottom).
The final dark-adaptation threshold was elevated 5.0 log
units. His visual field was constricted by confrontation to
about a 10 diameter O.D. and a 20 diameter O.S. His
full-field ERGs (Figure 3C) in response to 0.5-Hz white light
were nondetectable (i.e., less than 1.0 mV) andwere reduced
to 0.26 mVO.D. and 0.15 mVO.S in response to 30 Hz white
flicker. (NB: virtual blindness, i.e., loss of the ability to walk
independently in a well-lighted room, occurs when 30 Hz
cone flicker ERG responses are %0.05 mV). The decline in
visual acuity, visual fields, and full-field ERG amplitudes
showed considerable progression of his retinitis pigmen-
tosa over 18 years. His brother 218-479 (IV-2 in Figure 3A)
reported to us that he had had night deficiency since age
16 and loss of side vision inhis 40s. His retinitis pigmentosa
was diagnosed around age 16. Although he is two years
younger than 001-173, his vision was always worse than
that of his brother and gradually decreased to light percep-
tion in both eyes by age 54. Patient 218-479 has not had
a recent eye examination, and therefore no clinical records
were available for this study.
Mutations in splicing-factor genes associated with adRP
affect the amount and composition of the tri-snRNP and
thus lead to defects in its function11,16,17,20 and impair
the process of intron excision for specific pre-mRNA
substrates.20,24 To evaluate the pathogenicity of the identi-
fied DNA change and gain insights into the possible conse-
quences of this heterozygous missense, we immortalized
lymphoblast cells from both patients 001-173 and
218-479 upon transformation with the Epstein-Barr virus
and first analyzed the cellular localization of endogenous
PRPF6. Lymphoblasts from controls and patients were
grown on coverslips, fixed, and costained with an
anti-PRPF6 antibody that is specific to its N-terminal
moiety (Santa Cruz Biotechnology, Santa Cruz, CA) and
an antibody (Sigma-Aldrich, St. Louis, MO) recognizing
the SC35 protein, a marker for splicing speckles. Confocal
microscopy revealed that in all cell lines PRPF6 localized
in the nucleoplasm and splicing speckles (not shown),
similar to what has been observed in HeLa cells.15
However, lymphoblasts from patients revealed additional
accumulation of PRPF6 in round and sharply defined
subnuclear structures, which were identified as Cajal
bodies after specific staining with the anti-p80-coilinrican Journal of Human Genetics 88, 643–649, May 13, 2011 645
Figure 4. Confocal-Microscope Images of PRPF6 Localization in Lymphoblasts and HeLa Cells
Endogenous PRPF6 in lymphoblasts from patients 001-173 and 218-479 with p.Arg729Trp (A and B, respectively) and from a control
individual (C) is stained in green (rabbit anti-PRPF6 and donkey anti-rabbit FITC), and the p80-coilin is shown in red (mouse anti-
p80-coilin and donkey anti-mouse Texas red). In transfected HeLa cells, fluorescence originating from AcGFP-PRPF6-Arg729Trp (D)
and AcGFP-PRPF6-wt (E) are shown in green. p80-coilin (red) was visualized with the same antibodies as above. The white bar corre-
sponds to 10 mm; all images are at the samemagnification. Yellow signals in the overlay images indicate accumulation of PRPF6 in Cajal
bodies.antibody (Sigma-Aldrich) (Figures 4A and 4B). This did not
occur in control cells, for which colocalization of PRPF6
with p80-coilin was never observed (Figure 4C). Cajal
bodies are membraneless organelles involved in the final
stages of nuclear snRNP maturation14,25–27 and possibly
harbor the tri-snRNP regeneration steps that follow the
splicing process.28 When tri-snRNP assembly is impaired,
accumulation of immature snRNP complexes within these
structures is observed.14 Specific accumulation of PRPF6 in646 The American Journal of Human Genetics 88, 643–649, May 13,the Cajal bodies within nuclei of lymphoblasts from
patients with PRPF6 p.Arg729Trp therefore suggests an
impairment in tri-snRNP assembly or recycling; this
impairment is similar to what has been shown by other
methods for cells derived from patients with PRPF31,
PRPF3, and PRPF8 mutations.20
To gain further insights into this process, we cloned both
wild-type and mutant PRPF6 full-length cDNA into the
mammalian expression plasmid pAcGFP-C1 (Clontech,2011
Figure 5. RT-PCRs of Selected Endogenously Expressed Tran-
scripts in Lymphoblasts from Controls, Patients with
p.Arg729Trp, and Patients with Other PRPF31, PRPF3, and
PRPF8 Mutations
A panel of RT-PCRs encompassing five introns previously found to
be partially unspliced in lymphoblasts from patients with PRPF31,
PRPF3, and PRPF8 mutations is shown. Lane 1, molecular size
marker (Promega, Cat #G2101); lanes 2–16, lymphoblasts from
15 control individuals; lane 17, lymphoblasts from patient
001-173; lane 18, lymphoblasts from patient 218-479; lanes
19–21, lymphoblasts from patients with mutations in PRPF31,
PRPF3, or PRPF8 (positive controls). RT-PCRs performed on
HIST3H3 represent technical negative controls because this gene
is intronless. E#: exon harboring the forward or reverse RT-PCR
primer. Arrowheads indicate unspliced products.Mountain View, CA) to produce a PRPF6 fusion protein
with the green fluorescent protein from A. coerulescens
(AcGFP). Specifically, cDNA from a control human
lymphoblast library was amplified by PCR with the proof-
reading Pfu DNA polymerase (Promega, Madison, WI)
and primers 50-CGGAATTCCATGAACAAGAAGAAG-30
and 50-GGGGTACCTCAGAAGGTGTT-30. These matched
the PRPF6 sequence at their 30 moiety but carried artifi-
cially introduced restriction sites (underlined) for the
EcoRI and KpnI endonucleases, respectively, at their
50 end. We used these restriction sites to clone PCR prod-
ucts into the pAcGFP-C1 and produce plasmid AcGFP-
PRPF6-wild-type. We introduced the p.Arg729Trp change
into this latter plasmid by following the QuickChange
Site-Directed Mutagenesis protocol (Agilent Technologies,
La Jolla, CA) and using mutagenesis primers 50-GATGATG
GAGAAGGCGTGGGAAGCCTATAACC-30 and 50-GGTTA
TAGGCTTCCCACGCCTTCTCCATCATC-30 (the nucleo-
tide carrying themutation is underlined) to obtain plasmid
AcGFP-PRPF6-Arg729Trp. The sequence of all cloned DNA
was assessed by direct nucleotide sequencing, and it was
verified not to contain any unwanted variants. Imagery
of HeLa cells transfected with these constructs revealed
that the mutant fusions produced the same phenotypeThe Amedisplayed by cells with naturally occurring p.Arg729Trp
and that AcGFP-PRPF6-mut partly avoided splicing
speckles (Figure S1) and localized, unlike AcGFP-PRPF6-
wild-type, within Cajal bodies (Figures 4D and 4E). These
data demonstrate that mislocalized PRPF6 concerns only
mutated protein and that endogenous functional copies
of PRPF6 in HeLa cannot complement this phenotype.
We have previously demonstrated that patients with
mutations in PRPF31, PRPF3, and PRPF8 fail to correctly
splice introns from pre-mRNAs that probably carry specific,
yet unidentified, signals in their primary sequences.20
Specifically, cell lines from seven patients with different
mutations in these RP genes were unable to completely
excise five ‘‘signature’’ introns, out of a panel of 57 endoge-
nously transcribed sequences that recapitulated the
majority of splicing signals detected so far in humans and
displaying a wide range of gene expression. According to
a recently proposed model for the disease, this deficiency
in mRNAmaturation would lead to accumulation of defec-
tive transcripts or proteins as the first step in the molecular
pathologyofRP.20 Strikingly,whenanalyzed for their ability
to process the same panel of 57 introns, the two cell lines
with p.Arg729Trp displayed incomplete excision of four
out of five signature introns (Figure 5). These data indicate
that this PRPF6 mutation had an effect not only in
spliceosomal composition but also in general pre-mRNA
processing. Furthermore, they strongly indicate that
PRPF6 is a true RP gene; cells with p.Arg729Trp are defective
in excising specific introns thatwere found tobe incorrectly
processed only in patients with PRPF-associated RP.
In conclusion, we identify PRPF6 as the sixth splicing-
factor gene involved in autosomal-dominant retinitis pig-
mentosa. The mutation detected in a proband and his
affected brother is a missense mutation, as are many other
DNA changes that have been detected so far in RP genes
associated with the tri-snRNP. It concerns a uniquely
conserved residue in a HAT domain that is part of the
U4/U6 snRNP interaction region21 and therefore could
affect PRPF6 binding to the di-snRNP. It is presently
unclear whether mutated PRPF6 alleles would act as hap-
loinsufficient or dominant-negative elements.
Although many hypotheses linking defects in splicing-
factor genes and RP have been proposed (e.g.20,24,29–31),
most of them can be incorporated into two general models.
The first model postulates misplicing events affecting
mRNAs that are retina specific or are directly related to RP
(e.g., rhodopsin). The second proposes that splicing defects
could touchmorewidely expressed transcripts such as those
that were affected in cell lines from our patients, for which
no clear-cut relationship with retinal physiology has been
shown. In this case, RP would be the consequence of an
increased susceptibility of the retina to a general reduction
of splicing activity and/or to the continuous accumulation
of defective gene products. Although our results do not
clearly sustain one model over the other, they seem to fit
the second one better, and they certainly highlight the
central role of the tri-snRNP in themolecular etiology of RP.rican Journal of Human Genetics 88, 643–649, May 13, 2011 647
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